Priority Health to cover FoundationOne genomic profiles

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Priority Health announced it plans to cover the FoundationOne and FoundationOne Heme genomic profiles for patients with cancer developed by Foundation Medicine Inc.

FoundationOne interrogates the entire coding region in 315 genes and select introns in 28 genes commonly altered in solid tumors, according to Foundation Medicine. FoundationOne Heme analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies, sarcomas and select pediatric cancers.

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login